Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibodies binding to an intracellular PRL-1 OR PRL-3 polypeptide

A PRL-1, antibody technology, applied in the medical field, can solve the problem that the antibody cannot pass through the cell membrane and cannot approach the antigen, etc.

Inactive Publication Date: 2013-01-02
AGENCY FOR SCI TECH & RES
View PDF26 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Antibodies have not so far been used to target intracellular antigens or cancer markers because antibodies cannot pass through cell membranes and thus cannot access antigens

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibodies binding to an intracellular PRL-1 OR PRL-3 polypeptide
  • Antibodies binding to an intracellular PRL-1 OR PRL-3 polypeptide
  • Antibodies binding to an intracellular PRL-1 OR PRL-3 polypeptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 27

[0079] Example 27 shows that anti-PRL1 antibody 269 can bind to epitopes TYKNMR and TLNKFI. Accordingly, the present inventors provide anti-PRL antibodies such as anti-PRL1 antibodies that bind the sequence TYKNMR. The inventors also provide anti-PRL antibodies such as anti-PRL1 antibodies capable of binding TLNKFI. The anti-PRL antibody may have the ability to bind both sequences simultaneously.

[0080] Furthermore, Example 27 shows that anti-PRL3 antibodies can bind the epitopes KAKFYN and HTHKTR. Accordingly, the inventors provide anti-PRL antibodies such as anti-PRL3 antibodies that bind the sequence KAKFYN. The present inventors also provide anti-PRL antibodies such as anti-PRL3 antibodies capable of binding HTHKTR. The anti-PRL antibody may have the ability to bind both sequences simultaneously.

[0081] The anti-PRL antibody may comprise the variable region of antibody 269, the variable region of antibody 223 or the variable region of antibody 318, each of which is...

Embodiment 9

[0097] Example 9 describes the generation of PRL overexpressing tumors in mice and provides an animal model for metastasis and cancer therapy. Examples 10-12 demonstrate that animals treated with anti-PRL antibodies showed significantly lower metastatic lung tumors compared to animals not treated with anti-PRL antibodies. Specifically, the treated animals showed approximately 90% fewer tumors than untreated animals. The anti-PRL antibody is capable of binding and blocking the activity of a PRL polypeptide despite the intracellular localization of the PRL polypeptide. The inventors' studies represent the first demonstrations that metastasis can be effectively (approximately 90%) blocked by the use of monoclonal antibodies against the respective phosphatases despite their intracellular localization.

[0098] The present inventors have also shown that anti-PRL-3 monoclonal antibodies can effectively block the formation of metastases in the human ovarian cancer cell line A2780 ex...

Embodiment 1

[0445] Example 1. Cell lines: CHO-K1, A2780 and CT26

[0446] CHO-K1 cells, A2780 human ovarian cancer cells and CT26 mouse colon cancer cells were purchased from ATCC (Manassas, VA).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-I positive patients.

Description

[0001] This application is a divisional application of an invention patent application with an application date of May 3, 2008, an application number of 200880023052.3, and an invention title of "antibody that binds to intracellular PRL-1 polypeptide or PRL-3 polypeptide". technical field [0002] The invention relates to the fields of medicine, cell biology, molecular biology and biochemistry. The invention also relates to the medical field. [0003] In particular, the invention relates to the treatment and diagnosis of diseases, especially cancer, and compositions for such use. Background technique [0004] Cancer is a serious health problem worldwide. In 2007, an estimated 7.6 million people worldwide died of cancer. In the UK, for example, cancer kills 126,000 people every year. One in four people die from cancer. [0005] Known treatments for cancer include surgery, chemotherapy and radiation therapy. Many cancers can be cured if detected early enough. [0006] 10...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P35/00A61P35/04
CPCC07K2317/24A61K39/39558C07K2317/76C07K2317/77C07K16/40C07K2316/96A61K2039/505C07K16/18G01N33/57496C07K2317/34C07K2317/56C07K2317/73A61P35/00A61P35/04C07K16/30G01N2333/916A61K39/395A61K39/3955C12N5/0693C12N15/52G01N33/5005G01N33/53
Inventor 曾琦
Owner AGENCY FOR SCI TECH & RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com